Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2000

01-05-2000 | ORIGINAL ARTICLE

Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer

Authors: Ralf Axel Hilger, Gabriele Jacek, Carsten Oberhoff, Susanne Kredtke, Joachim Baumgart, Siegfried Seeber, Max Ernst Scheulen

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2000

Login to get access
Metadata
Title
Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer
Authors
Ralf Axel Hilger
Gabriele Jacek
Carsten Oberhoff
Susanne Kredtke
Joachim Baumgart
Siegfried Seeber
Max Ernst Scheulen
Publication date
01-05-2000
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800051023

Other articles of this Issue 6/2000

Cancer Chemotherapy and Pharmacology 6/2000 Go to the issue

ORIGINAL ARTICLE

Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans

ORIGINAL ARTICLE

Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations

ORIGINAL ARTICLE

Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer

ORIGINAL ARTICLE

The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma

ORIGINAL ARTICLE

Induction of oocyte maturation by jun-N-terminal kinase (JNK) on the oncogenic ras-p21 pathway is dependent on the raf-MEK-MAP kinase signal transduction pathway

CLINICAL TRIAL REPORT

Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits